JPMorgan says there's a new GLP-1 drug player and it can rally 80%

Structure Therapeutics could one day boast a competitive obesity product and go up against Eli Lilly and the like, according to JPMorgan.

Related Keywords

Hardik Parikh ,Eli Lilly ,Novo Nordisk ,Structure Therapeutics ,Analyst Hardik Parikh ,